Literature DB >> 11193164

Prevention and reduction of AD-type pathology in PDAPP mice immunized with A beta 1-42.

D Games1, F Bard, H Grajeda, T Guido, K Khan, F Soriano, N Vasquez, N Wehner, K Johnson-Wood, T Yednock, P Seubert, D Schenk.   

Abstract

In AD certain brain structures contain a pathological density of A beta protein deposited into plaques. The effect of genetic mutations found in early onset AD patients was an overproduction of A beta 42, strongly suggesting that overproduction of A beta 42 is associated with AD. We hypothesized that an immunological response to A beta 42 might alter its turnover and metabolism. Young PDAPP transgenic mice were immunized with A beta 1-42, which essentially prevented amyloid deposition; astrocytosis was dramatically reduced and there was reduction in A beta-induced inflammatory response as well. A beta 1-42 immunization also appeared to arrest the progression of amyloidosis in older PDAPP mice. A beta immunization appears to increase clearance of amyloid plaques, and may therefore be a novel and effective approach for the treatment of AD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11193164     DOI: 10.1111/j.1749-6632.2000.tb06936.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  9 in total

1.  Complex pharmacokinetics of a humanized antibody against human amyloid beta peptide, anti-abeta Ab2, in nonclinical species.

Authors:  Yulia Vugmeyster; Pam Szklut; David Wensel; John Ross; Xin Xu; Michel Awwad; Davinder Gill; Lioudmila Tchistiakov; Garvin Warner
Journal:  Pharm Res       Date:  2011-03-18       Impact factor: 4.200

2.  Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody.

Authors:  M Enari; E Flechsig; C Weissmann
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-24       Impact factor: 11.205

3.  Combination therapy prevents amyloid-dependent and -independent structural changes.

Authors:  Gauri Malthankar-Phatak; Shane Poplawski; Nikhil Toraskar; Robert Siman
Journal:  Neurobiol Aging       Date:  2011-01-22       Impact factor: 4.673

4.  Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer's disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development.

Authors:  Avindra Nath; Elizabeth Hall; Marnia Tuzova; Michael Dobbs; Melina Jons; Caroline Anderson; Jerold Woodward; Zhihong Guo; Weiming Fu; Richard Kryscio; David Wekstein; Charles Smith; William R Markesbery; Mark P Mattson
Journal:  Neuromolecular Med       Date:  2003       Impact factor: 3.843

5.  Selective vulnerability of dentate granule cells prior to amyloid deposition in PDAPP mice: digital morphometric analyses.

Authors:  Chi-Cheng Wu; Faisal Chawla; Dora Games; Russell E Rydel; Stephen Freedman; Dale Schenk; Warren G Young; John H Morrison; Floyd E Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-26       Impact factor: 11.205

Review 6.  Is passive immunization for Alzheimer's disease 'alive and well' or 'dead and buried'?

Authors:  Gregory A Jicha
Journal:  Expert Opin Biol Ther       Date:  2009-04       Impact factor: 4.388

Review 7.  Spines, plasticity, and cognition in Alzheimer's model mice.

Authors:  Tara Spires-Jones; Shira Knafo
Journal:  Neural Plast       Date:  2011-11-28       Impact factor: 3.599

8.  Vascular consequences of passive Abeta immunization for Alzheimer's disease. Is avoidance of "malactivation" of microglia enough?

Authors:  Steven W Barger
Journal:  J Neuroinflammation       Date:  2005-01-11       Impact factor: 8.322

9.  Evaluation of a DNA Aβ42 vaccine in adult rhesus monkeys (Macaca mulatta): antibody kinetics and immune profile after intradermal immunization with full-length DNA Aβ42 trimer.

Authors:  Doris Lambracht-Washington; Min Fu; Pat Frost; Roger N Rosenberg
Journal:  Alzheimers Res Ther       Date:  2017-04-26       Impact factor: 6.982

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.